We suggest that the combination of high-quality neoantigen fitness model and elevated T lymphocyte-specific gene signature together with histopathological verification of tumor infiltration by CD8+ T cells should be used in current clinical trials of IDH wild-type GBM for the identification of those patients who have the highest likelihood of clinical response to immune therapy. Here, CD8A is linked to neoplasm.